Atlas Trials

Platinum-Resistant Primary Peritoneal Carcinoma

25 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Platinum-Resistant Primary Peritoneal Carcinoma

RecordFirmDate
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (NCT05271318)TILT Biotherapeutics Ltd.2022-05-17
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04781088)Floor Backes, MD2021-09-01
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors (NCT04616534)National Cancer Institute (NCI)2021-06-01
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04753216)Northwestern University2021-03-16
Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) (NCT04678102)Seoul National University Hospital2020-12-17
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552)Atreca, Inc.2020-02-11
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer (NCT04055649)Ira Winer2020-01-21
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04019288)M.D. Anderson Cancer Center2019-12-03
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03907527)Precigen, Inc2019-04-30
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03587311)National Cancer Institute (NCI)2018-10-12
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03206047)National Cancer Institute (NCI)2017-11-08
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986)Roswell Park Cancer Institute2017-07-14
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207)National Cancer Institute (NCI)2017-05-19
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03026062)M.D. Anderson Cancer Center2017-05-18
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707)Mayo Clinic2014-02-24

Track Platinum-Resistant Primary Peritoneal Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.